insights on current FDA-approved monoclonal antibodies against Ebola virus infection
O Tshiani Mbaya, P Mukumbayi… - Frontiers in immunology, 2021 - frontiersin.org
The unprecedented 2013-2016 West Africa Ebola outbreak accelerated several medical
countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational …
countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational …
The roles of Ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development
Ebola virus (EBOV) is a highly lethal pathogen that has caused several outbreaks of severe
hemorrhagic fever in humans since its emergence in 1976. The EBOV glycoprotein (GP1, 2) …
hemorrhagic fever in humans since its emergence in 1976. The EBOV glycoprotein (GP1, 2) …
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus
GS Mohan, W Li, L Ye, RW Compans, C Yang - PLoS pathogens, 2012 - journals.plos.org
In addition to its surface glycoprotein (GP1, 2), Ebola virus (EBOV) directs the production of
large quantities of a truncated glycoprotein isoform (sGP) that is secreted into the …
large quantities of a truncated glycoprotein isoform (sGP) that is secreted into the …
Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
Zaire ebolavirus (ZEBOV) can be transmitted by human-to-human contact and causes acute
haemorrhagic fever with case fatality rates up to 90%. There are no effective therapeutic or …
haemorrhagic fever with case fatality rates up to 90%. There are no effective therapeutic or …
A shared structural solution for neutralizing ebolaviruses
Sudan virus (genus Ebolavirus) is lethal, yet no monoclonal antibody is known to neutralize
it. We here describe antibody 16F6 that neutralizes Sudan virus and present its structure …
it. We here describe antibody 16F6 that neutralizes Sudan virus and present its structure …
Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: an immuno-informatics approach
Ebola virus (EBOV), a non-segmented single-stranded RNA virus, is often-most transmitted
through body fluids like sweat, tears, saliva, and nasal secretions. Till date, there is no …
through body fluids like sweat, tears, saliva, and nasal secretions. Till date, there is no …
Discovery of an antibody for pan-ebolavirus therapy
W Furuyama, A Marzi, A Nanbo, E Haddock… - Scientific reports, 2016 - nature.com
During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody
therapy (eg, ZMapp) was utilized to treat patients. However, due to the antigenic differences …
therapy (eg, ZMapp) was utilized to treat patients. However, due to the antigenic differences …
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
Ebola virus (EBOV) causes acute hemorrhagic fever in humans and non-human primates
with mortality rates up to 90%. So far there are no effective treatments available. This study …
with mortality rates up to 90%. So far there are no effective treatments available. This study …
Interaction between TIM-1 and NPC1 is important for cellular entry of Ebola virus
M Kuroda, D Fujikura, A Nanbo, A Marzi… - Journal of …, 2015 - Am Soc Microbiol
Multiple host molecules are known to be involved in the cellular entry of filoviruses, including
Ebola virus (EBOV); T-cell immunoglobulin and mucin domain 1 (TIM-1) and Niemann-Pick …
Ebola virus (EBOV); T-cell immunoglobulin and mucin domain 1 (TIM-1) and Niemann-Pick …
Ebolavirus comparative genomics
The 2014 Ebola outbreak in West Africa is the largest documented for this virus. To examine
the dynamics of this genome, we compare more than 100 currently available ebolavirus …
the dynamics of this genome, we compare more than 100 currently available ebolavirus …